Resmetirom improves liver fibrosis in nonalcoholic steatohepatitis
1. In this randomized controlled trial, among patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, resmetirom was superior to placebo ...
1. In this randomized controlled trial, among patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, resmetirom was superior to placebo ...
1. Patients in the sleeve gastrectomy and Roux-en-Y bypass groups reported significantly greater resolution of NASH compared to those in ...
1. Nonalcoholic steatohepatitis (NASH) resolution without worsening of fibrosis occurred in a significantly greater percentage of patients who received semaglutide ...
1. The gut virome among patients with severe NAFLD was found to be different than those with milder NAFLD. #2. ...
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH) Evidence Rating Level: 1 ...
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH) Evidence Rating Level: 1 ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.